Talphera (TLPH)
NASDAQ:TLPH
Want to see TLPH full AI Analyst Report?
TLPH Stock Chart & Stats
$1.10
-$0.04(-6.10%)
At close: 4:00 PM EST
$1.10
-$0.04(-6.10%)
Day’s Range― - ―
52-Week Range$0.38 - $1.57
Previous CloseN/A
Volume42.81K
Average Volume (3M)2.97M
Market Cap
$42.35M
Enterprise Value$12.92M
Total Cash (Recent Filing)$21.11M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Aug 19, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding51,899,647
10 Day Avg. Volume675,544
30 Day Avg. Volume2,969,035
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)2.84
Price to Sales (P/S)1726.72
P/FCF Ratio-4.25
Enterprise Value/Market Cap0.31
Enterprise Value/Revenue12.92K
Enterprise Value/Gross Profit12.92K
Enterprise Value/Ebitda-0.83
Forecast
1Y Price Target
$3.17Price Target Upside187.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.28
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Clean Balance SheetZero reported debt and positive equity give Talphera structural financial flexibility to fund clinical execution or seek non-dilutive partners. Over 2–6 months this balance-sheet buffer reduces immediate solvency risk and supports the company through trial readouts and regulatory activities.
Clear Enrollment Path To PMASurpassing 50% enrollment with a plan to finish in 2026 and a 2027 PMA target shortens regulatory timelines. The short 24/72 hour endpoints enable rapid LPO-to-topline conversion, making clinical milestones a tangible near-term de-risking event for the business model and commercialization path.
Strong Site/KOL EngagementHigh investigator engagement and KOL endorsement create durable advantages for enrollment quality, protocol adherence, and post-approval adoption. Sustained clinical championing improves external validity of results and can accelerate hospital formulary acceptance if approvals succeed.
Bears Say
Minimal Revenue; Large Net LossVirtually no operating revenue and a multi‑million net loss indicate Talphera is not yet a self-sustaining commercial business. Over several months this margin profile means continued reliance on external capital or milestone financing, and little current capacity to absorb unexpected development delays.
Persistent Negative Operating Cash FlowConsistent ~-$11M annualized cash burn demonstrates structural funding need; absent material revenue, ongoing negative operating cash flow increases refinancing risk and can force dilutive financings or program delays if milestone receipts or tranches are interrupted.
Reliance On Conditional Financing TranchesDependence on milestone‑contingent tranches creates execution‑linked funding risk: if enrollment, timing or data flow slip, anticipated capital may not materialize. This structural financing contingency can affect trial completion, regulatory timelines, and strategic options over the next several quarters.
Talphera News
TLPH FAQ
What was Talphera’s price range in the past 12 months?
Talphera lowest stock price was $0.38 and its highest was $1.57 in the past 12 months.
What is Talphera’s market cap?
Talphera’s market cap is $42.35M.
When is Talphera’s upcoming earnings report date?
Talphera’s upcoming earnings report date is Aug 19, 2026 which is in 80 days.
How were Talphera’s earnings last quarter?
Talphera released its earnings results on May 13, 2026. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.067 by $0.027.
Is Talphera overvalued?
According to Wall Street analysts Talphera’s price is currently Undervalued.
Does Talphera pay dividends?
Talphera does not currently pay dividends.
What is Talphera’s EPS estimate?
Talphera’s EPS estimate is -0.06.
How many shares outstanding does Talphera have?
Talphera has 51,899,647 shares outstanding.
What happened to Talphera’s price movement after its last earnings report?
Talphera reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.067. Following the earnings report the stock price went down -0.444%.
Which hedge fund is a major shareholder of Talphera?
Currently, no hedge funds are holding shares in TLPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Talphera Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.17 (187.88% Upside)
$3.17 (187.88% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 5.7%
Last 30 Days ▼ 5.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.75%
12-Months-Change
Fundamentals
Return on Equity
-92.98%
Trailing 12-Months
Asset Growth
101.10%
Trailing 12-Months
Company Description
Talphera
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. Talphera, Inc. was incorporated in 2005 and is headquartered in San Mateo, California.
TLPH Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical and operational momentum: enrollment has surpassed the 50% milestone, sites and KOLs reported favorable feedback on dosing simplicity and stability, and management expects a rapid top-line read in H2 2026 with a PMA plan for 2027. However, the company faces higher operating expenses and depends on two conditional financing tranches (~$16M) to fund the path to potential approval, with enrollment variability and financing contingency as primary risks. Overall, positive progress is balanced against execution and financing risk, but the highlights outweigh the lowlights.View all TLPH earnings summariesTLPH Stock 12 Month Forecast
Average Price Target
$3.17
▲(187.88% Upside)
Technical Analysis
Ownership Overview
5.94% Insiders
1.48% Mutual Funds
38.89% Other Institutional Investors
52.84% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---